Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-38P is a member of the U2 small nuclear RNA pseudogene family. The canonical U2 snRNA is an essential component of the major spliceosome complex, playing a critical role in the recognition of the branch site during pre-mRNA splicing[1][2]. However, RNU2-38P, as denoted by the “pseudogene” designation, represents a nonfunctional, noncoding locus that does not produce a functional small RNA. True or functional U2 snRNAs (e.g., RNU2-1, RNU2-2) participate directly in the splicing process and, when mutated, are implicated in inherited disease and some cancers[2]. Pseudogenes such as RNU2-38P do not encode for active RNAs and are not incorporated into the spliceosome complex. As such, they lack biological function, are not disease-associated targets, and have no known role in therapeutics, drug interactions, or biomarker development. Additional context: Active U2 snRNA genes (such as RNU2-1, RNU2-2) are critical for mRNA processing and mutations in those can result in severe neurodevelopmental syndromes or contribute to oncogenesis[2]. However, pseudogenes like RNU2-38P are genomic relics, often arising through gene duplication or retrotransposition, but they are typically transcriptionally inactive and lack conserved function. No evidence is present in the scientific literature for a functional, disease, or pharmacological role for RNU2-38P. Summary: RNU2-38P is a nonfunctional pseudogene; it is not a receptor, enzyme, transporter, or drug discovery target, and does not possess known biological or disease relevance[2]. If you seek a spliceosomal snRNA with functional or clinical importance, RNU2-1 (“RNA, U2 small nuclear 1”), or RNU2-2 (“RNA, U2 small nuclear 2”) should be considered instead[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 38, pseudogene (RNU2-38P).